All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
AACR 2017 | Poster 2033/5 – Testing the combined effects of low dose olaparib plus ibrutinib on Mantle Cell Lymphoma cytotoxicity
On Monday 3rd April during this year’s American Association for Cancer Research (AACR) annual meeting, a poster (2033 / 5) by Adam D. Curtis, from the Eastern Maine Medical Center, Brewer, ME, et al. titled “Testing the combined effects of low dose olaparib plus ibrutinib on MCL cytotoxicity” was presented.
The group aimed to potentially improve ibrutinib therapy for MCL by combining it with olaparib, a DNA damage response inhibitor, and testing the combination in MCL cells in vitro.
Key Highlights:
- Ibrutinib monotherapy is cytotoxic to MCL cell lines but only at high doses (>25μM)
- MCL growth is more sensitive to olaparib that ibrutinib
- Olaparib monotherapy treatment is cytotoxic to MCL cell lines at lower concentrations (10μM) than ibrutinib
- Low doses of ibrutinib combined with olaparib inhibited MCL cell growth more than either drug alone at concentrations <EC50
- The ibrutinib-olaparib combination increases apoptosis and MCL cell death
The poster was concluded by hypothesizing that ibrutinib combined with olaparib potentially could improve response rate and duration in patients with MCL, as well as reducing adverse events.
References
- Curtis A.D. et al. Testing the combined effects of low dose olaparib plus ibrutinib on MCL cytotoxicity [Poster]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2017. Poster nr [2033 / 5].
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?